Labcorp to Spin Off Clinical Development Business
Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction. The planned spin-off will ...
North Carolina United States Adam Schechter Hogan Lovells Clinical Development Business York Stock Exchange
Source: pharmiweb.com